Morimoto M, Maishi N, Hida K
Cancer Drug Resist. 2024; 7:1.
PMID: 38318528
PMC: 10838380.
DOI: 10.20517/cdr.2023.121.
Takasago T, Hayashi R, Ueno Y, Ariyoshi M, Onishi K, Yamashita K
PLoS One. 2023; 18(3):e0283822.
PMID: 36996146
PMC: 10062630.
DOI: 10.1371/journal.pone.0283822.
Salmon H, Remark R, Gnjatic S, Merad M
Nat Rev Cancer. 2019; 19(4):215-227.
PMID: 30867580
PMC: 7787168.
DOI: 10.1038/s41568-019-0125-9.
Tian Y, Chen K, Zulkefli N, Maner R, Hsieh C
Molecules. 2018; 23(12).
PMID: 30558243
PMC: 6321194.
DOI: 10.3390/molecules23123327.
Maishi N, Ohba Y, Akiyama K, Ohga N, Hamada J, Nagao-Kitamoto H
Sci Rep. 2016; 6:28039.
PMID: 27295191
PMC: 4904795.
DOI: 10.1038/srep28039.
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor M, Choi H, Hansen J
J Clin Invest. 2016; 126(5):1885-96.
PMID: 27064283
PMC: 4855933.
DOI: 10.1172/JCI85086.
The role of angiogenic factors in endometrial cancer.
Zyla M, Kostrzewa M, Litwinska E, Szpakowski A, Wilczynski J, Stetkiewicz T
Prz Menopauzalny. 2015; 13(2):122-6.
PMID: 26327841
PMC: 4520350.
DOI: 10.5114/pm.2014.42714.
Implantation of fibrin gel on mouse lung to study lung-specific angiogenesis.
Mammoto T, Mammoto A
J Vis Exp. 2014; (94).
PMID: 25548859
PMC: 4396947.
DOI: 10.3791/52012.
Novel enhanced green fluorescent protein-expressing NOG mouse for analyzing the microenvironment of xenograft tissues.
Higuchi Y, Kawai K, Yamamoto M, Kuronuma M, Ando Y, Katano I
Exp Anim. 2014; 63(1):55-62.
PMID: 24521863
PMC: 4160926.
DOI: 10.1538/expanim.63.55.
Can nanomedicines kill cancer stem cells?.
Zhao Y, Alakhova D, Kabanov A
Adv Drug Deliv Rev. 2013; 65(13-14):1763-83.
PMID: 24120657
PMC: 4174448.
DOI: 10.1016/j.addr.2013.09.016.
Opportunities and challenges for successful use of bevacizumab in pediatrics.
Barone A, Rubin J
Front Oncol. 2013; 3:92.
PMID: 23641361
PMC: 3638307.
DOI: 10.3389/fonc.2013.00092.
Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery.
Li Z, Cho C
J Transl Med. 2012; 10 Suppl 1:S1.
PMID: 23046982
PMC: 3445867.
DOI: 10.1186/1479-5876-10-S1-S1.
Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?.
Kozin S, Duda D, Munn L, Jain R
J Natl Cancer Inst. 2012; 104(12):899-905.
PMID: 22572994
PMC: 3379722.
DOI: 10.1093/jnci/djs239.
Tumor Vascular Morphology Undergoes Dramatic Changes during Outgrowth of B16 Melanoma While Proangiogenic Gene Expression Remains Unchanged.
Langenkamp E, Vom Hagen F, Zwiers P, Moorlag H, Schouten J, Hammes H
ISRN Oncol. 2012; 2011:409308.
PMID: 22235379
PMC: 3249352.
DOI: 10.5402/2011/409308.
Antiangiogenesis enhances intratumoral drug retention.
Ma J, Chen C, Blute T, Waxman D
Cancer Res. 2011; 71(7):2675-85.
PMID: 21447737
PMC: 3070759.
DOI: 10.1158/0008-5472.CAN-10-3242.
Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer.
Wang H, Marchal G, Ni Y
World J Radiol. 2011; 3(1):1-16.
PMID: 21286490
PMC: 3030722.
DOI: 10.4329/wjr.v3.i1.1.
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models.
Fukumura D, Duda D, Munn L, Jain R
Microcirculation. 2010; 17(3):206-25.
PMID: 20374484
PMC: 2859831.
DOI: 10.1111/j.1549-8719.2010.00029.x.
Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer.
Seshadri M, Toth K
Transl Oncol. 2009; 2(3):121-7.
PMID: 19701496
PMC: 2730133.
DOI: 10.1593/tlo.09103.
Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.
Seshadri M, Bellnier D, Cheney R
Int J Radiat Oncol Biol Phys. 2008; 72(4):1198-207.
PMID: 18954713
PMC: 2582978.
DOI: 10.1016/j.ijrobp.2008.07.043.
Imaging angiogenesis and the microenvironment.
Fukumura D, Jain R
APMIS. 2008; 116(7-8):695-715.
PMID: 18834413
PMC: 2859845.
DOI: 10.1111/j.1600-0463.2008.01148.x.
